Cardinal Health (NYSE:CAH) is a prominent player in the healthcare services and products industry, providing pharmaceuticals and medical products to over 100,000 locations daily. Competing with major firms like McKesson and AmerisourceBergen, Cardinal Health has shown resilience and growth in a competitive market. On January 27, 2026, Cowen & Co. maintained its "Buy" rating for CAH, with the stock priced at $210.93.
TD Cowen raised its price target for Cardinal Health from $225 to $233, indicating confidence in the company's future performance. This optimism is supported by the stock's recent 1.25% increase, closing at $210.93, which outperformed the S&P 500's 0.5% gain, as highlighted by the latest trading session data.
Over the past month, Cardinal Health's shares have risen by 0.02%, outperforming the Medical sector's decline of 0.63%. However, it slightly trailed the S&P 500's 0.18% gain. Investors are eagerly awaiting the company's earnings release on February 5, 2026, with an expected EPS of $2.33, a 20.73% increase from the previous year.
The Zacks Consensus Estimate forecasts Cardinal Health's revenue to reach $64.33 billion, marking a 16.41% rise from the prior year. For the full fiscal year, earnings are projected at $9.93 per share. The company's market capitalization is approximately $50.12 billion, with a trading volume of 1,076,104 shares on the NYSE.
